Lupin receives Tentative Approval from U.S. FDA for Doxycycline Capsules

Global pharma major Lupin Limited (Lupin) has received tentative approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Doxycycline Capsules, 40 mg, to market a generic equivalent of Oracea® Capsules, 40 mg, of Galderma Laboratories, L.P.

Doxycycline Capsules (RLD Oracea®) had estimated annual sales of USD 215 million in the U.S. (IQVIA MAT September 2022).

Shares of Lupin Limited was last trading in BSE at Rs. 709.80 as compared to the previous close of Rs. 710.70. The total number of shares traded during the day was 59124 in over 3395 trades.

The stock hit an intraday high of Rs. 723.80 and intraday low of 706.45. The net turnover during the day was Rs. 42247645.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 TentativeApproval USFDA ANDA DoxycyclineCapsules